| Table 2a |
| HLA type |
Allele |
Healthy control (n=20705) |
Breast cancer patients
(n=173) |
SYFPEITHI score |
Recognition site |
BIMAS |
Recognition site |
| A |
*24:02 |
35.9 |
29.3 |
12 |
YQDTILWKDIFHKNNQLALT |
― |
|
| |
*02:01 |
11.5 |
11.8 |
20 |
YQDTILWKDIFHKNNQLALT |
2.8 |
YQDTILWKDIFHKNNQLALT |
| |
*02:06＊ |
9.2 |
16.8 |
0 |
|
― |
|
| |
*11:01 |
9.1 |
8.7 |
17 |
YQDTILWKDIFHKNNQLALT |
2.4 |
YQDTILWKDIFHKNNQLALT |
| |
*31:01＊ |
8.6 |
20.5 |
0 |
|
3.6 |
YQDTILWKDIFHKNNQLALT |
| |
*26:01 |
7.5 |
4 |
0 |
|
― |
|
| B |
*52:01 |
11.1 |
26 |
― |
|
13.2 |
YQDTILWKDIFHKNNQLALT |
| |
*51:01 |
9.0 |
6.6 |
14 |
YQDTILWKDIFHKNNQLALT |
4.4 |
YQDTILWKDIFHKNNQLALT |
| |
*35:01＊ |
8.2 |
17.9 |
― |
|
1 |
YQDTILWKDIFHKNNQLALT |
| |
*40:02 |
7.8 |
7.1 |
0 |
|
― |
|
| |
*15:01 |
7.8 |
8.4 |
11 |
YQDTILWKDIFHKNNQLALT |
― |
|
| |
*54:01 |
7.6 |
13.9 |
― |
|
― |
|
| |
＊ |
|
|
|
|
|
|
| |
*44:03 |
6.5 |
6 |
0 |
|
15 |
YQDTILWKDIFHKNNQLALT |
| |
*07:02 |
5.6 |
3.3 |
13 |
YQDTILWKDIFHKNNQLALT |
― |
|
| |
*40:01 |
5.3 |
5.3 |
14 |
YQDTILWKDIFHKNNQLALT |
— |
|
| |
*46:01 |
4.8 |
7 |
— |
|
— |
|
| |
*40:06 |
4.6 |
4.7 |
|
|
— |
|
| |
*39:01 |
3.4 |
3.3 |
24 |
YQDTILWKDIFHKNNQLALT |
27 |
YQDTILWKDIFHKNNQLALT |
| |
*48:01 |
2.8 |
4.4 |
— |
|
— |
|
| |
・ |
・ |
・ |
・ |
・ |
・ |
・ |
| |
・ |
・ |
・ |
・ |
・ |
・ |
・ |
| |
・ |
・ |
・ |
・ |
・ |
・ |
・ |
| |
*39:02 |
0.3 |
0.6 |
11 |
YQDTILWKDIFHKNNQLALT |
— |
|
|
| Table 2b |
| AB |
Allele |
Healthy control (n=20705) |
Breast cancer patients (n=173) |
Breast cancer patients (n=173) |
Recognition site |
IEDB Analysis |
Recognition site |
| DRB1 |
*09:01 |
14.1 |
35.9 |
0 |
|
|
|
| |
*04:05＊ |
13.7 |
8.4 |
0 |
|
|
|
| |
*15:02 |
10.5 |
10.8 |
0 |
|
4.64 |
YQDTILWKDIFHKNNQLALT |
| |
*08:03 |
8.6 |
7.9 |
0 |
|
|
|
| |
*15:01 |
7.7 |
8.7 |
20 |
YQDTILWKDIFHKNNQLALT |
|
YQDTILWKDIFHKNNQLALT |
| |
*01:01 |
5.8 |
3.7 |
18 |
YQDTILWKDIFHKNNQLALT |
|
YQDTILWKDIFHKNNQLALT |
| |
*13:02 |
5.7 |
5.5 |
0 |
|
2.4 |
|
| |
*08:02 |
4.2 |
3.7 |
0 |
|
2.76 |
|
| |
*12:01＊ |
3.7 |
7.5 |
0 |
|
|
|
| |
*11:01 |
2.7 |
3.7 |
24 |
YQDTILWKDIFHKNNQLALT |
4.33 |
YQDTILWKDIFHKNNQLALT |
|
Table 2: HLA alleles of the patients and healthy donors with predicted affinity scores
a)The percentages of the HLA types of both healthy donors and breast cancer patients in Japan are shown in parallel with the SYFPEITHI, BIMAS, and IEDB analyses scores.
b)Recognized sequences are shown as underlined text. (―) means the allele and the peptide affinity could not be simulated by the algorithm. |
